Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

Vanillin flavouring in vapes may disrupt embryo development

Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...

Heart valve tissues created from stem cells

The breakthrough should help advance our understanding into how human heart valves develop,...

Breast augmentation procedure uses 3D-printed scaffolds

3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...

Content from other channels on our network

Crushing economics: scaling up canola processing in Australia

The added benefits of bacteria from the cheese-making process

From six weeks to three days: Australian software overhauls US manufacturer's label approvals

Saputo to sell its UK operations to Lactalis

Bulla Dairy Foods appoints Peter Hall as Chief Executive Officer

Top 3 benefits of aerobic and strength training for chronic disease prevention

32-bed specialist private mental health hospital opens today

$100K fine follows tower crane incident that caused hospital roof collapse

Nexon partners with Dementia Australia to tackle dementia stigma in the workplace

"Migrant worker exploitation" sees NSW aged care provider repay nearly $120K

Researchers recover silver from end‍-‍of‍-‍life solar panels

Muting in practice: when safety becomes a vulnerability

Nozomi Networks and Sophos partner to combine OT and IT security ops

Digital transformation for automotive product manufacturer

Winner of Propel‍-‍AIR robotics and AI sprint announced